H7 Portfolio News | Arthrosi Enters USD 1.5 Billion Acquisition Agreement with Sobi 🎉🎉

We’re excited to share that Sobi® (STO:SOBI) has agreed to acquire Arthrosi Therapeutics (Arthrosi) in a transaction valued at up to $1.5 billion, including $950 million upfront and up to $550 million in milestone payments. H7 BioCapital participated in Arthrosi’s most recent financing round. The deal is expected to close in the first half of 2026.

Arthrosi is a late-stage biotech company developing next-generation treatments for gout. Through this acquisition, Sobi strengthens its gout portfolio with pozdeutinurad (AR882), a once-daily oral URAT1 inhibitor currently in two global Phase III trials. Both studies have completed patient enrollment, covering progressive and tophaceous gout, with key data expected in 2026. Pozdeutinurad has the potential to become a best-in-class treatment for patients with inadequate response to first-line therapies. 

Transaction details

Under the terms of the agreement, Sobi will pay $950 million upfront in cash to acquire Arthrosi, together with up to $550 million in cash in clinical, regulatory and sales milestones. The transaction is subject to the satisfaction of customary closing conditions and is expected to close in H1 2026. 

About Pozdeutinurad

Pozdeutinurad (AR882) is an investigational URAT1 inhibitor being developed for the treatment of progressive and tophaceous gout and has completed Phase 2 studies that demonstrated compelling efficacy with a sustained reduction of serum uric acid, dissolution of tophi and a well-tolerated safety profile.  It is currently being evaluated in two Phase 3 studies, REDUCE 1 and REDUCE 2, two twelve-month, randomized, double-blind, placebo-controlled studies to assess pozdeutinurad's ability to reduce sUA in patients with progressive and tophaceous gout. Both Phase 3 studies are now fully enrolled, and the pivotal data is expected in 2026.

About Arthrosi

Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with progressive gout. The rights to pozdeutinurad in Greater China are held by ApicHope.

About Sobi

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion.